Oncotype DX® and St. Gallen Guidelines 2013

We are pleased to announce the publication of the St Gallen Guidelines published by an Expert panel of 51 members from 21 countries. We can notice that the utilization of multi-gene test Oncotype DX® is now widely accepted and mentioned in the St Gallen Guidelines 2013. The 21-gene RS is accepted by the Expert Panel as providing not only prognostic, but also predictive information regarding the prescription of cytotoxic therapy in addition to endocrine therapy for patients with luminal disease. More information can find at website: